McKesson fiscal 2024 EPS outlook includes consensus

• McKesson's (NYSE:MCK) fiscal 2024 non-GAAP EPS outlook range of $26.10 to $26.90 includes the consensus estimate of $26.28.
• This equates to 1%-4% year-over-year growth.
• In fiscal 2024 Q4, rose 104% year over year to $824M ($7.19 per diluted share vs. $5.83).
• The drugs wholesaler saw a more modest 4% year-over-year increase in revenue to ~$68.9B.
• The stock is up ~4% in after-hours trading.
• Revenue in its largest segment, U.S. pharmaceutical, grew 15% year over year to $61.7B, due to increased volume of specialty products and market growth.
• In the long term, McKesson (MCK) sees 5%-7% growth in U.S. pharmaceutical; 11%-12% growth in prescription technology solutions; and 10%-12% growth in medical-surgical solutions.
• McKesson (MCK) ended the quarter with cash and cash equivalents of ~$4.7B, a ~32% increase from March 31, 2022.

More on McKesson

• McKesson: Strong Free Cash Flow, But Shares To The Expensive Side Vs. History

• McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth